134 related articles for article (PubMed ID: 37562330)
1. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
Brunner AM; Huggar D; Copher R; Zhou ZY; Zichlin ML; Anderson A; Downes N; McBride A
Leuk Res; 2023 Sep; 132():107353. PubMed ID: 37562330
[TBL] [Abstract][Full Text] [Related]
2. The impact of remission duration on the long-term economic burden of acute myeloid leukemia among patients without hematopoietic stem cell transplant in the United States.
Tabah A; Brady BL; Huggar D; Jariwala-Parikh K; Huey K; Copher R; LeBlanc TW
J Med Econ; 2022; 25(1):903-911. PubMed ID: 35723576
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
Hagiwara M; Sharma A; Chung KC; Delea TE
J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
[TBL] [Abstract][Full Text] [Related]
5. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
6. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
7. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
[TBL] [Abstract][Full Text] [Related]
9. Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes.
Dharmani C; Wang E; Tu N; Fofah O; Cueto J; Salas M; Kamel YM
Future Oncol; 2023 Aug; 19(24):1677-1693. PubMed ID: 37345543
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database.
Dharmani C; Wang E; Tu N; Salas M; Kamel YM
Future Oncol; 2023 Jan; 19(2):159-171. PubMed ID: 36912693
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020.
Huntington SF; Ingham MP; Okonkwo L; Singh A; Wang R; Ammann EM
Leuk Lymphoma; 2022 May; 63(5):1180-1190. PubMed ID: 34913805
[TBL] [Abstract][Full Text] [Related]
12. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
14. Trends in the treatment of acute myeloid leukaemia in the elderly.
Lang K; Earle CC; Foster T; Dixon D; Van Gool R; Menzin J
Drugs Aging; 2005; 22(11):943-55. PubMed ID: 16323971
[TBL] [Abstract][Full Text] [Related]
15. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse.
Irish W; Ryan M; Gache L; Gunnarsson C; Bell T; Shapiro M
Curr Med Res Opin; 2017 Mar; 33(3):519-527. PubMed ID: 27966377
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.
Kabra M; Margotto L; Manuguid F
Future Oncol; 2021 Jul; 17(21):2769-2784. PubMed ID: 33881356
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
19. Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis.
Joshi N; Kale H; Corman S; Wert T; Hill K; Zeidan AM
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e248-e254. PubMed ID: 33422471
[TBL] [Abstract][Full Text] [Related]
20. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
Cheng WY; Satija A; Cheung HC; Hill K; Wert T; Laliberté F; Lefebvre P
Hematology; 2021 Dec; 26(1):261-270. PubMed ID: 33631084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]